- Direction
- Deteriorating
- Own history
- 16th
- Peers
- 52th
- Persistence
- EMERGING
· Pharmaceutical Preparations
RESEARCH SNAPSHOTAurinia Pharmaceuticals Inc.'s latest supported as-filed period reports revenue of $83.7M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 55.40% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 13.93% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 52.24% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 90.08% · CORE
Level · gp.fundamentals.operating_margin
Raw value 42.25% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 19.85% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 7.32% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 18.9%; Operating margin moved 2700 bp higher; Operating income increased 130.7%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents increased 239.7%; Operating cash flow increased 18.8%.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 13.9%; Operating margin moved 176 bp higher; Operating income increased 18.9%.
3 evidence-backed componentsCurrent assets changed +32.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
AUPH · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001600620-26-000075SEC ↗8-KOct 30, 2026Period Oct 30, 20260001600620-26-000074SEC ↗4Sep 11, 2026Period Sep 10, 20260001600620-26-000068SEC ↗4Aug 25, 2026Period Aug 21, 20260001837798-26-000013SEC ↗8-KAug 19, 2026Period Aug 19, 20260001600620-26-000066SEC ↗10-QAug 6, 2026Period Jun 30, 20260001600620-26-000062SEC ↗8-KAug 6, 2026Period Aug 6, 20260001600620-26-000059SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 10, 2026Filed Sep 11, 2026 | Robertson Stephen P.Chief Legal Officer | Open Market SaleDirect | 11,939 | $16 | $190,427 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Robertson Stephen P.Chief Legal Officer | Open Market SaleDirect | 20,975 | $17 | $355,946 | Form 4 ↗ |
| Jun 4, 2026Filed Jun 8, 2026 | Goetz KathleenDirector | Grant Or AwardDirect | 23,931 | $0 | $0 | Form 4 ↗ |
| Jun 4, 2026Filed Jun 8, 2026 | Nova Tina SusanDirector | Grant Or AwardDirect | 23,931 | $0 | $0 | Form 4 ↗ |
| Jun 4, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Current assets changed +34.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Total assets changed +57.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed +33.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed +35.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current liabilities changed +27.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed +130.7% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001370348-26-000002| Bailey Jeffrey AllenDirector |
| Grant Or AwardDirect |
| 23,931 |
| $0 |
| $0 |
| Form 4 ↗ |
| Jun 4, 2026Filed Jun 8, 2026 | Johnson Craig ADirector | Grant Or AwardDirect | 23,931 | $0 | $0 | Form 4 ↗ |
| Jun 2, 2026Filed Jun 2, 2026 | TANG KEVINChief Executive Officer | OtherIndirect | 10,000 | $2 | $16,500 | Form 4 ↗ |
| Jun 2, 2026Filed Jun 2, 2026 | TANG KEVINChief Executive Officer | Open Market PurchaseIndirect | 206,005 | $15 | $3.1M | Form 4 ↗ |
| Jun 1, 2026Filed Jun 2, 2026 | TANG KEVINChief Executive Officer | Open Market PurchaseIndirect | 343,521 | $15 | $5.2M | Form 4 ↗ |
| Jun 1, 2026Filed Jun 2, 2026 | TANG KEVINChief Executive Officer | Open Market PurchaseIndirect | 99 | $15 | $1,519 | Form 4 ↗ |
| May 29, 2026Filed Jun 2, 2026 | TANG KEVINChief Executive Officer | Open Market PurchaseIndirect | 262,682 | $15 | $4.0M | Form 4 ↗ |
| May 29, 2026Filed Jun 2, 2026 | TANG KEVINChief Executive Officer | Open Market PurchaseIndirect | 2,299 | $15 | $35,290 | Form 4 ↗ |
| May 18, 2026Filed May 20, 2026 | Hearne Michael SChief Financial Officer | Grant Or AwardDirect | 116,144 | $0 | $0 | Form 4 ↗ |
| May 18, 2026Filed May 20, 2026 | Hearne Michael SChief Financial Officer | Grant Or AwardDirect | 70,230 | $0 | $0 | Form 4 ↗ |
| May 18, 2026Filed May 20, 2026 | Cole RyanChief Operating Officer | Grant Or AwardDirect | 116,144 | $0 | $0 | Form 4 ↗ |
| May 18, 2026Filed May 20, 2026 | Cole RyanChief Operating Officer | Grant Or AwardDirect | 70,230 | $0 | $0 | Form 4 ↗ |
| May 18, 2026Filed May 20, 2026 | Robertson Stephen P.Chief Legal Officer | Grant Or AwardDirect | 115,541 | $0 | $0 | Form 4 ↗ |
| Mar 6, 2026Filed Mar 10, 2026 | Keenan GregSVP, Chief Medical Officer | Tax WithholdingDirect | 8,069 | $14 | $115,548 | Form 4 ↗ |
| Mar 3, 2026Filed Mar 3, 2026 | TANG KEVINDirector | Open Market PurchaseIndirect | 184,208 | $14 | $2.6M | Form 4 ↗ |
| Mar 2, 2026Filed Mar 3, 2026 | Miller Joseph MChief Financial Officer | Tax WithholdingDirect | 37,511 | $14 | $533,031 | Form 4 ↗ |